Cwm LLC Takes $59,000 Position in LifeMD, Inc. (NASDAQ:LFMD)

Cwm LLC purchased a new position in LifeMD, Inc. (NASDAQ:LFMD) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 11,350 shares of the company’s stock, valued at approximately $59,000.

Other hedge funds also recently bought and sold shares of the company. Quest Partners LLC bought a new position in LifeMD in the 2nd quarter worth about $31,000. EntryPoint Capital LLC bought a new position in LifeMD in the 1st quarter worth about $89,000. Los Angeles Capital Management LLC bought a new position in LifeMD in the 2nd quarter worth about $88,000. SG Americas Securities LLC bought a new position in LifeMD in the 3rd quarter worth about $70,000. Finally, The Manufacturers Life Insurance Company bought a new position in LifeMD in the 2nd quarter worth about $93,000. Institutional investors own 35.52% of the company’s stock.

LifeMD Price Performance

Shares of NASDAQ:LFMD opened at $4.29 on Monday. The firm’s 50 day moving average price is $4.95 and its 200-day moving average price is $6.91. LifeMD, Inc. has a twelve month low of $4.10 and a twelve month high of $12.88. The company has a quick ratio of 0.83, a current ratio of 0.87 and a debt-to-equity ratio of 10.83. The stock has a market capitalization of $179.14 million, a PE ratio of -5.80 and a beta of 1.18.

LifeMD (NASDAQ:LFMD) last released its earnings results on Wednesday, August 7th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The business had revenue of $50.66 million for the quarter, compared to the consensus estimate of $48.47 million. During the same quarter last year, the firm posted ($0.23) EPS. Equities research analysts expect that LifeMD, Inc. will post -0.49 EPS for the current year.

Analysts Set New Price Targets

LFMD has been the subject of a number of recent analyst reports. B. Riley initiated coverage on LifeMD in a research report on Friday, August 23rd. They issued a “buy” rating and a $11.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 target price on shares of LifeMD in a research report on Friday, September 20th. Finally, KeyCorp decreased their target price on LifeMD from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, LifeMD has a consensus rating of “Buy” and a consensus target price of $12.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.